CEA-negative glioblastoma and melanoma cells are sensitive to cytosine deaminase-5-fluorocytosine therapy directed by the carcinoembryonic antigen promoter

• Autorzy: Dabrowska A. , Szary J. , Kowalczuk M. , Szala S. , Ugorski M.
• Języki publikacji: EN

Abstrakty

EN

Recent studies have suggested that carcinoembryonic antigen (CEA)-promoter se­quences are active only in CEA-positive cells, filing in the criteria for tumor specific targeting of suicide genes. However, the present study on gene therapy of colon can­cer and cell-specificity of CEA promoter, provide evidence that CEA-positive and CEA-negative cells transfected with E. coli cytosine deaminase (CD) gene under the control of CEA promotor sequence are sensitive to enzyme/pro-drug therapy with 5-fluorocytosine (5-FC). Individual clones derived from the CEA-negative cell lines: melanoma Hs294T and glioblastoma T98G after transfection with CD differed pro­foundly in their sensitivity to 5-FC. The IC50 values for several clones of the CEA-neg- ative cells were almost the same as for CEA-positive colon cancer cells. Such 5-FC-sensitive clones derived from the population of CEA-negative cells, present even in small number, because of the very effective bystender effect of this en­zyme/pro-drug system can cause severe problems during therapy by efficiently kill­ing surrounding normal cells. Safety is the major issue in gene therapy. Our data sug­gest that the safety of gene-directed enzyme pro-drug therapy (GDEPT) with CEA promoter driven expression of therapeutic genes is not so obvious as it has originally been claimed.

Słowa kluczowe

EN

5-fluorocytosine; cytosine deaminase; therapy; carcinoembryonic antigen promoter; melanoma cell; Escherichia coli

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2004
• Tom: 51
• Numer: 3
• Opis fizyczny: p.723-732,fig.,ref.

Twórcy

autor

Dabrowska A.

• Polish Academy of Sciences, Weigla Street 12, 53-114 Wroclaw, Poland

autor

Szary J.

autor

Kowalczuk M.

autor

Szala S.

autor

Ugorski M.

Bibliografia

• Cao G, Kuriyama S, Gao J, Mitoro A, Cui L, Nakatani T, Zhang X, Kikukawa M, Pan X, Fukui H, Qi Z. (1998) Comparison of carcinoembryonic antigen promoter regions isolated from human colorectal carcinoma and normal adjacent mucosa to induce strong tumor-selective gene expression. Int J Cancer.; 78: 242-7.
• Cao G, Kuriyama S, Gao J, Kikukawa M, Cui L, Nakatani T, Zhang X, Tsujinoue H, Pan X, Fukui H, Qi Z. (1999a) Effective and safe gene therapy for colorectal carcinoma using the cytosine deaminase gene directed by the carcinoembryonic antigen promoter. Gene Ther.; 6: 83-90.
• Cao G, Kuriyama S, Cui L, Nagao S, Pan X, Toyokawa Y, Zhang X, Nishiwaki I, Qi Z. (1999b) Analysis of the human carcinoembryonic antigen promoter core region in colorectal carcinoma-selective cytosine deaminase gene therapy. Cancer Gene Therapy.; 6: 572-80.
• Chung-Faye GA, Kerr DJ, Young LS, Searle PF. (2000) Gene therapy strategies for colon cancer. Mol Med Today.; 6: 82-7.
• Cournoyer D, Beauchemin N, Boucher D, Benchimol S, Fuks A, Stanners CP. (1988) Transcription of genes of the carcinoembryonic antigen family in malignant and nonmalignant human tissues. Cancer Res.; 48: 3153-7.
• DiMaio JM, Clary BM, Via DF, Coveney E, Pappas TN, Lyerly HK. (1994) Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery.; 116: 205-13.
• Fichera A, Michelassi F, Arenas RB. (1998) Selective expression of carcinoembryonic antigen promoter in cancer strategy for gene therapy in colorectal cancer. Dis Colon Rectum.; 41: 747-54.
• Finkelstein SD, Sayegh R, Christensen S, Swalsky PA. (1993) Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type Cancer.; 71: 3827-38.
• Freeman SM, Whartenby KA, Freeman JL, Abboud CN, Marrogi AJ. (1996) In situ use of suicide genes for cancer therapy. Semin Oncol.; 23: 31-45.
• Grunert F, AbuHarfeil N, Schwarz K, von Kleist S. (1985) Two CEA and three NCA species, although distinguishable by monoclonal antibodies, have nearly identical peptide patterns. Int J Cancer.; 36: 357-62.
• Holness CL, Simmons DL. (1994) Structural motifs for recognition and adhesion in members of the immunoglobulin superfamily. JCell Sci.; 107: 2065-70.
• Huber BE, Austin EA, Richards CA, Davis ST, Good SS. (1994) Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA.; 91: 8302-6.
• Kijma T, Osaki T, Nishino K, Kumagai T, Funakoshi T, Goto H, Tachibana I, Tanio Y, Kishimoto T. (1999) Application of the Cre recombinase/loxP system further enhances antitumor effects in cell type-specific gene therapy against carcinoembryonic antigen-producing cancer. Cancer Res.; 59: 4906-11.
• Krop-Watorek A, Laskowska A, Salwa J, Klopcki AG, Grunert F, Ugorski M. (1999) CEA-related proteins on human urothelial cell lines of different transformation grades. Cancer Lett.; 139: 15-22.
• Kurane S, Krauss JC, Watari E, Kannagi R, Chang AE, Kudoh S. (1998) Targeted gene transfer for adenocarcinoma using a combination of tumor-specific antibody and tissue specific promoter. Jpn J Cancer Res.; 89: 1212-9.
• Lan KH, Kanai F, Shiratori Y, Okabe S, Yoshida Y, Wakimoto H, Hamada H, Tanaka T, Ohashi M, Omata M. (1996) Tumor-specific gene expression in carcinoembryonic antigen-producing gastric cancer cells using adenovirus vectors. Gastroenterology.; 111: 1241-51.
• Lan KH, Kanai F, Shiratori Y, Ohashi M, Tanaka T, Okudaira T, Yoshida Y, Hamada H, Omata M. (1998) In vivo gene expression and therapy mediated by adenoviral vectors for human carcinoembryonic antigen-producing gastric carcinoma. Cancer Res.; 57: 4279-84.
• Moolten FL, Wells JM. (1990) Curability of tumors bearing herpes thymidine kinase genes transferred by retrovirus vectors. J Natl Cancer Inst.; 82: 297-300.
• Moolten FL. (1986) Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res.; 46: 5276-81.
• Mullen CA, Coale MM, Lowe R, Blease RM. (1994) Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild-type tumor. Cancer Res.; 54: 1503-6.
• Osaki T, Tanio Y, Tachibana I, Hosoe S, Kumagai T, Kawase I, Oikawa S, Kishimoto T. (1994) Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res.; 54: 5258-61.
• Richards CA, Austin EA, Huber BE. (1995) Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Hum Gene Ther.; 6: 881-93.
• Schreve H, Thompson J, Bona M, Hefta LJF, Maruya A, Hassayer M, Shively JE, von Kleist S, Zimmermann W. (1990) Cloning of the complete gene for carcinoembryonic antigen: analysis of its promoter indicates a region conveying cell type- specific expression. Mol Cell Biol.; 10: 2738-48.
• Seregni E, Bombardieri E, Bogni A, Crippa F, Dejager E, Buraggi GL. (1992) The role of serum carcinoembryonic antigen (CEA) in the management of patients with colorectal carcinoma: the experience of the Instituto Tumori of Milan. Int J Biol Markers.; 7: 167-70.
• Shively JE, Beatty JD. (1985) CEA-related antigens: molecular biology and clinical significance. Crit Rev Oncol Hematol.; 2: 355-99.
• Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. (199) 0New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst.; 82: 1107-12.
• Szala S, Missol E, Sochanik A, Strozyk M. (1996) The use of cationic liposomes DC-CHOL/DOPE and DDAB/DOPE for direct transfer of Eschericha coli cytosine deaminase gene into growing melanoma tumors. Gene Therapy.; 3: 1026-31.
• Tanaka T, Kanai F, Okabe S, Yoshida Y, Wakimoto H, Hamada H, Shiratori Y, Lan K-H, Ishitobi M, Omata M. (1996) Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. Cancer Res.; 56: 1341-5.
• Tanaka T, Kanai F, Lan K-H, Ohashi M, Shiratori Y, Yoshida Y, Hamada H, Omata M. (1997) Adenovirus-mediated gene therapy of gastric carcinoma using cancer-specific gene expression in vivo. Biochem Biophys Res Commun.; 231: 775-9.
• Tanaka S, Iwai M, Morikawa T, Muramatsu A, Mori T, Okanoue Okanoue T, Kashima K, Maruyama-Tabata H, Hirai H, Satoh E, Imanishi J, Mazda O. (2000) Targeted killing of carcinoembryonic antigen (CEA)-producing cholangiocarcinoma cells by polyamidoamine dendrimer-mediated transfer of an Epstein-Barr virus (EBV)-based plasmid vector carrying the CEA promoter. Cancer Gene Ther.; 7: 1241-9.
• Thompson JA, Grunert F, Zimmermann W. (1991) Carcinoembryonic antigen gene family: Molecular biology and clinical perspectives. J Clin Lab Anal.; 5: 344-66.
• Ueda K, Iwahashi M, Nakamori M, Nakamura M, Yamaue H, Tanimura H. (2000) Enhanced selective gene expression by adenovirus vector using Cre/loxP regulation system for human carcinoembryonic antigen-producing carcinoma. Oncology..; 59: 255-65.
• Ueda K, Iwahashi M, Nakamori M, Nkamura M, Matsuura I, Ojima T, Yamaue H. (2003) Improvement of carcinoembryonic antigen-specific prodrug gene therapy for experimental colon cancer. Surgery.; 133: 309-17.
• Wagner HE, Toth CA, Steele GD Jr, Thomas P. (1992) Metastatic potential of human colon cancer cell lines: relationship to cellular differentiation and carcinoembryonic antigen production. Clin Exp Metastasis.; 10: 25-31.